{
    "nct_id": "NCT00018343",
    "title": "Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen",
    "status": "COMPLETED",
    "last_update_time": "2009-01-20",
    "description_brief": "This study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "estrogen (examples used in AD trials: 17\u03b2\u2011estradiol; conjugated equine estrogens)"
    ],
    "placebo": [
        "placebo (e.g., placebo transdermal patch or oral placebo used in randomized trials)"
    ],
    "explanation_target": [
        "Reason: The study description says the intervention is estrogen given to women with Alzheimer's to evaluate \"beneficial effects... on cognitive function\" \u2014 the stated intent is to improve cognition rather than to target specific AD pathology (amyloid or tau). Estrogen is a steroid hormone (small molecule), and in these trials it is tested as a cognition-modulating/neuroprotective agent rather than a targeted biologic.",
        "Act: Key trial examples and drug details from the literature \u2014 pilot and randomized trials have used 17\u03b2\u2011estradiol (transdermal patches) and conjugated equine estrogens (oral) vs placebo to assess cognition in postmenopausal women with AD. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Act (evidence summary): Some small pilot studies reported short-term cognitive benefits with estradiol patches, while larger randomized trials and meta-analyses generally failed to show sustained cognitive improvement and raised safety/efficacy concerns. Representative sources: pilot transdermal estradiol study; randomized trials including the Alzheimer\u2019s Disease Cooperative Study; systematic reviews/Cochrane analyses. \ue200cite\ue202turn0search1\ue202turn0search3\ue202turn0search4\ue201",
        "Reflect: Classification rationale \u2014 because the intervention is estrogen given to improve cognitive function (not described as targeting amyloid/tau or using biologic agents like antibodies), it best fits the 'cognitive enhancer' category. If a trial instead explicitly targeted AD pathology with a mechanism-modifying approach, it would be reclassified, but that is not indicated here. \ue200cite\ue202turn0search9\ue202turn0search0\ue201",
        "Web search results (selected): 1) Pilot placebo-controlled double\u2011blind study of transdermal 17\u03b2\u2011estradiol in postmenopausal women with AD (reported cognitive/neuroendocrine responses). \ue200cite\ue202turn0search1\ue201 2) Randomized trial by the Alzheimer's Disease Cooperative Study of estrogen replacement in mild\u2013moderate AD showing no cognitive/global benefit over 12 months. \ue200cite\ue202turn0search3\ue201 3) Randomized 16\u2011week trial of conjugated equine estrogens vs placebo in women with AD (no significant cognitive benefit). \ue200cite\ue202turn0search5\ue201 4) Cochrane/systematic reviews concluding no sustained cognitive benefit from estrogen replacement in women with AD and noting potential harms. \ue200cite\ue202turn0search4\ue202turn0search0\ue201"
    ],
    "agent_type": "L) Growth Factors and Hormones",
    "explanation_agent": [
        "Reason: The intervention is estrogen (a steroid hormone) given to improve cognition/neuroprotection in women with AD rather than to directly target amyloid-\u03b2 or tau pathology, so it maps to the CADRO category for hormones/growth factors.",
        "Act: Trial drugs listed (17\u03b2\u2011estradiol, conjugated equine estrogens) are hormone replacement therapies tested as cognitive enhancers/neuroprotective agents in AD (examples: pilot transdermal 17\u03b2\u2011estradiol study; larger randomized ADCS estrogen replacement trial; other short-term RCTs). \ue200cite\ue202turn0search5\ue202turn0search0\ue202turn0search4\ue201",
        "Reflect: CADRO does not have a separate \"cognitive enhancer\" bucket; the most specific match for a hormone-based intervention is L) Growth Factors and Hormones. The trials cited evaluated estrogen's effects on cognition but did not primarily act as amyloid- or tau-modifying biologics, so L is the appropriate CADRO classification.",
        "Web search results (selected): 1) ADCS randomized trial\u2014estrogen replacement in mild\u2013moderate AD, no cognitive/global benefit over 12 months. \ue200cite\ue202turn0search0\ue201 2) Pilot placebo-controlled transdermal 17\u03b2\u2011estradiol study showing short-term cognitive/neuroendocrine responses. \ue200cite\ue202turn0search5\ue201 3) Short-term randomized controlled trial reporting early cognitive effects with transdermal estradiol but limited/short-lived benefits. \ue200cite\ue202turn0search4\ue201 4) Cochrane/systematic reviews concluding no sustained cognitive benefit of estrogen replacement in women with AD and noting safety concerns. \ue200cite\ue202turn0search3\ue201 5) Systematic review/meta-analysis of HRT and cognition summarizing heterogeneous trial results. \ue200cite\ue202turn0search1\ue201"
    ]
}